Trial Profile
ADDUCE: A randomized, double-blind, placebo-controlled, dose-ranging pilot study of the efficacy and safety of GC811007 in subjects with type-2 diabetes mellitus and heart failure: To assess safety and to determine whether treatment with GC811007 (400 and 1200 mg/day) improves exercise tolerance and indexes of cardiac structure and function
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Trientine (Primary)
- Indications Diabetic cardiomyopathy
- Focus Therapeutic Use
- Acronyms ADDUCE
- Sponsors Protemix Corporation
- 13 Jul 2012 New trial record